Skip to main content
SpringerLink
Log in

Dementia with Lewy Bodies

Clinical Features and Treatment

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Dementia with Lewy bodies (DLB) accounts for 15 to 20% of late-onset dementias. The overlap of cognitive symptoms, neuropsychiatric features, parkinsonism and severe sensitivity to antipsychotic drugs raise a number of key management issues.

The neurochemical profile of DLB provides a good theoretical rationale for the potential value of cholinesterase inhibitor therapy, which is supported by clinical evidence from a number of case series and one placebo-controlled double-blind trial. It appears that cholinesterase inhibitor treatment is well tolerated and improves fluctuating confusion, cognition and psychotic symptoms; however, the evidence can still only be considered preliminary and a further double-blind study is imperative.

Given the high prevalence of severe sensitivity to antipsychotic drugs in patients with DLB, their role in the treatment of psychiatric symptoms and behavioural problems is uncertain, although a small case report literature indicates that some patients may benefit. On the current balance of evidence, prescription of antipsychotic agents to patients with DLB is not recommended, although further studies focussing on patients with severe and intractable neuropsychiatric symptoms are required.

Provisional case series indicate a high degree of motor response to levodopa therapy, although controlled trials are a priority to carefully evaluate the benefits in the context of possible adverse effects, such as the exacerbation of psychosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Neurology 1996; 47: 1113–24

    Article  PubMed  CAS  Google Scholar 

  2. Byrne EJ, Lennox G, Lowe J. Diffuse Lewy body disease, clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989; 52: 709–17

    Article  PubMed  CAS  Google Scholar 

  3. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer’s disease: a clinical and pathological entity. Neurology 1990; 40: 1–8

    Article  PubMed  CAS  Google Scholar 

  4. Perry RH, Irving D, Blessed G, et al. A clinically and pathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119–39

    Article  PubMed  CAS  Google Scholar 

  5. McKeith IG, Perry RH, Fairbairn AF, et al. Operational criteria for senile dementia of Lewy body type. Psychol Med 1992; 22: 911–22

    Article  PubMed  CAS  Google Scholar 

  6. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity & inter-rater reliability of clinical diagnostic criteria for SDLT. Neurology 1994; 44: 872–7

    Article  PubMed  CAS  Google Scholar 

  7. Ballard CG, Lowery K, Harrison R, et al. Non-cognitive symptoms in dementia with Lewy bodies. In: Perry RH, McKeith IG, Perry EK, et al., editors. Dementia with Lewy bodies. New York: Cambridge University Press, 1996: 67–84

    Chapter  Google Scholar 

  8. Galasko D, Katzman R, Salmon DP, et al. Clinical and neuropathological findings in Lewy body dementia. Brain Cogn 1996; 31: 166–75

    Article  PubMed  CAS  Google Scholar 

  9. Klakta LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: findings in 28 pathologically diagnosed cases. Neurology 1996; 47: 1148–52

    Article  Google Scholar 

  10. Weiner WF, Risser RC, Cullum CM, et al. Alzheimer’s disease and its Lewy body variant: a clinical analysis of post-mortem verified cases. Am J Psychiatry 1996; 153: 1269–73

    PubMed  CAS  Google Scholar 

  11. Ala TA, Yang K-H, Sung JH, et al. Hallucinations and signs of parkinsonism help distinguish patients with Alzheimer’s disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997; 62: 16–21

    Article  PubMed  CAS  Google Scholar 

  12. Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry 1999; 156: 1039–45

    PubMed  CAS  Google Scholar 

  13. Ballard CG, Mohan RNC, Patel A, et al. Idiopathic clouding of consciousness — do the patients have cortical Lewy body disease? Int J Geriatr Psychiatry 1993; 8: 571–6

    Article  Google Scholar 

  14. Shergill S, Mullen E, D’Ath P, et al. What is the clinical prevalence of Lewy Body dementia? Int J Psychiatry 1994; 9: 907–12

    Article  Google Scholar 

  15. Ballard C, O’Brien J, Swann A, et al. One year follow up of parkinsonism in dementia with Lewy bodies. Dementia 2000; 11: 219–22

    CAS  Google Scholar 

  16. Gnanalingham KK, Burne EJ, Thornton A, et al. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 1997 Mar; 62: 243–52

    Article  PubMed  CAS  Google Scholar 

  17. Ballard CG, Shaw F, Lowery K, et al. The prevalence, assessment and association of falls in dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord 1998; 10: 97–103

    Article  Google Scholar 

  18. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000; 177: 252–6

    Article  PubMed  CAS  Google Scholar 

  19. Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy Bodies, Alzheimer’s disease and vascular dementia. Neurology 2000; 54: 1616–25

    Article  PubMed  CAS  Google Scholar 

  20. Perry EK, Walker MP, Grace J, et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness. Trends Neurosci 1999; 22: 273–80

    Article  PubMed  CAS  Google Scholar 

  21. Kaufer DI, Catt Ke, Lopez EL, et al. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998; 51: 1512

    Article  PubMed  CAS  Google Scholar 

  22. Ballard C, Ayre G, Gray A. Psychotic symptoms and behavioural disturbances in dementia: a review. Rev Neurol 1999; 155Suppl. 45: 44–52

    Google Scholar 

  23. McShane R, Keene J, Gedling K, et al. Hallucinations, cortical Lewy body pathology, cognitive function and neuroleptic use in dementia. In: Perry RH, McKeith IG, Perry EK, editors. Dementia with Lewy bodies. New York: Cambridge University Press, 1996: 414–37

    Google Scholar 

  24. McKeith I, Fairbairn A, Poerry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673–8

    Article  PubMed  CAS  Google Scholar 

  25. McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346(8976): 699

    Article  PubMed  CAS  Google Scholar 

  26. Ballard C, Grace J, McKeith I, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998; 351: 1032–3

    Article  PubMed  CAS  Google Scholar 

  27. Imamura T, Hirono N, Hashimoto M, et al. Clinical diagnosis with Lewy bodies in a Japanese dementia registry. Dement Geriatr Cogn Disord 1999; 10(3): 210–6

    Article  PubMed  CAS  Google Scholar 

  28. Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease; and in relation to neuroleptic medication. Neuroscience 2000; 98: 79–87

    Article  PubMed  CAS  Google Scholar 

  29. Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy Body disease. Brain Cogn 1996; 31: 148–65

    Article  PubMed  CAS  Google Scholar 

  30. Langlais PJ, Thal L, Hansen L, et al. Neurotransmitters in basal ganglia and cortex of Alzheimer’s disease with and without Lewy bodies. Neurology 1993; 43: 1927–34

    Article  PubMed  CAS  Google Scholar 

  31. Perry EK, Marshall E, Kerwin JM. Evidence of a monoaminergic cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990; 55: 1454–6

    Article  PubMed  CAS  Google Scholar 

  32. Liberini P, Valerio A, Memo M, et al. Cholinergic therapy and Lewy body dementia. In: Perry RH, McKeith IG, Perry EK, editors. Dementia with Lewy bodies. New York: Cambridge University Press, 1996: 414–37

    Chapter  Google Scholar 

  33. Ayre GA, Sahgal A, McKeith I, et al. Distinct profiles of neuropsychological impairment in dementia with Lewy bodies and Alzheimer’s disease. Neurology. In press

  34. Ellis RJ, Caligiuri M, Galasko D, et al. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Dis Assoc Disord 1996; 10(2): 103–14

    Article  PubMed  CAS  Google Scholar 

  35. Levy R, Eagger S, Griffiths M, et al. Lewy bodies and response to tacrine in Alzheimer’s disease. Lancet 1994 Jan; 343: 176

    Article  PubMed  CAS  Google Scholar 

  36. Hutchinson M, Fazzini E. Cholinesterase inhibitors in Parkinson’s disease [letter]. J Neurol Neurosurg Psychiatry 1996; 61: 324–5

    Article  PubMed  CAS  Google Scholar 

  37. Lebert F, Pasquier F, Souliez L, et al. Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998; 13: 516–9

    Article  PubMed  CAS  Google Scholar 

  38. Shea C, MacKnight C, Rockwood R. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10: 229–39

    Article  PubMed  CAS  Google Scholar 

  39. Aarsland D, Bronnick K, Karlsen K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999; 14: 69–72

    Article  PubMed  CAS  Google Scholar 

  40. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiary 2000; 15: 280–1

    Article  CAS  Google Scholar 

  41. Blakey A, Braude W, Jenkins J, et al. The use of cholinesterase inhibitors in dementia with Lewy bodies [abstract]. Proceedings of the International Psychogeriatric Association and Royal College of Psychiatrists Faculty of Old Age Conference; 2000 Apr 4–7; Newcastle upon Tyne

  42. McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. J Geriatr Psychiatry 2000; 15: 387–92

    Article  CAS  Google Scholar 

  43. McKeith IG, Del Ser T, Anand R. Rivastigmine provides symptomatic benefit in dementia with Lewy Bodies: findings from a placebo-controlled International Multicenter Study [abstract]. Neurology 2000 Apr; 54Suppl. 3: 450

    Google Scholar 

  44. Geroldi C, Frisoni GB, Bianchetti A, et al. Drug treatment in Lewy body dementia. Dement Geriatr Cogn Disord 1997; 8: 188–97

    Article  PubMed  CAS  Google Scholar 

  45. Williams SW, Byrne EJ, Stokes P. The treatment of diffuse Lewy body disease: a pilot study. Int J Geriatr Psychiatry 1993; 8: 731–9

    Article  Google Scholar 

  46. Ballard C, O’Brien J. Treating behavioural and psychological signs in Alzheimer’s disease. BMJ 1999; 319; 138–79

    Article  PubMed  CAS  Google Scholar 

  47. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for the psychosis and behavioural disturbances associated with dementia: a randomised, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60(2): 107–15

    Article  PubMed  CAS  Google Scholar 

  48. De Deyn PP, Rabberu K, Rasmussen A, et al. Arandomised trial of risperidone, placebo and haloperidol for behavioural symptoms in dementia. Neurology 1999 Sept; 54(5): 946–55

    Article  Google Scholar 

  49. Anonymous. Low-dose clozapine for the treatment of druginduced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999; 340(10): 757–63

    Google Scholar 

  50. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 1999; 14(3): 484–7

    Article  PubMed  CAS  Google Scholar 

  51. Allen RL, Walker Z, D’Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995; 346: 185

    Article  PubMed  CAS  Google Scholar 

  52. Lee H, Cooney JM, Lewer BA. Case report: the use of risperidone, an atypical neuroleptic in Lewy body disease. Int J Geriatr Psychiatry 1994; 9: 415–7

    Article  Google Scholar 

  53. Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999; 14: 459–66

    Article  PubMed  CAS  Google Scholar 

  54. Parsa MA, Greenaway HM, Bastani B. Treatment of psychosis in patients with Parkinson’s disease and dementia (Lewy body disease variant) with quetiapine [abstract plus oral presentation]. Neurology 2000 Apr; Suppl. 3: 451–2

    Google Scholar 

  55. Ballard C, Walker M. Neuropsychiatric aspects of Alzheimer’s disease. Curr Pyschiatry Rep 1999; 1: 49–60

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, NE4 6BE, England

    Sandra Campbell, Sally Stephens &  Clive Ballard

Authors
  1. Sandra Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sally Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clive Ballard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clive Ballard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campbell, S., Stephens, S. & Ballard, C. Dementia with Lewy Bodies. Drugs & Aging 18, 397–407 (2001). https://doi.org/10.2165/00002512-200118060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118060-00002

Keywords

Search

Navigation